Acute myeloid leukemia in children and adolescents
Conditions
Interventions
AML-nonAPL Venetoclax+CRNIT GROUP:The combination of targeted therapy and chemotherapy was applied in the treatment of reduction of volume, induction therapy, consolidation therapy and maintenance the
AML-nonAPL CRNIT GROUP:The combination of targeted therapy and chemotherapy was applied in the treatment of reduction of volume, induction therapy, consolidation therapy and maintenance therapy, and o
APL GROUP:Venetoclax was routinely used for APL reduction therapy, arsenic agent combined with ATRA was applied in induction therapy, consolidation therapy and maintenance therapy, and for patients wh
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed of AML; 2. Patients younger than 18 years old; 3. Patients who haven't received pre-treatment, except for those who receive single IT injection or Hydroxycarbamide or low-dose Ara-c for Leukocytosis (no more than 300mg/m2); 4. Patients or/and their guardian who have signed the Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1. Junior Myelomonocytic Leukemia; 2. Mixed Phenotype Acute Leukemia; 3. Patients who received any anti-tumor treatment within 2 weeks, except for those who received single IT injection or Hydroxycarbamide or low-dose Ara-c for Leukocytosi; 4. Patients complicated with any other diseases or psychiatric disease that could affect their safety and compliance, informed consent, participation, follow-up or interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRD;Bone marrow remission status;Drug toxicity; | — |
Countries
China
Contacts
Public ContactHuyong Zheng
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed